Invasive Fungal Disease IFD Infection Diagnostic Reagent

Invasive Fungal Disease IFD Infection Diagnostic Reagent Market Outlook

The global Invasive Fungal Disease (IFD) Infection Diagnostic Reagent Market is expected to reach approximately USD 1.2 billion by 2035, growing at a Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period from 2025 to 2035. The rising incidence of fungal infections, particularly among immunocompromised patients, alongside the growing awareness of the importance of timely and accurate diagnosis, is a significant growth factor for this market. Advances in diagnostic technologies, including the development of rapid and sensitive testing methods, are also contributing to market expansion. Furthermore, the increasing investments in healthcare infrastructure and research aimed at improving diagnostic capabilities for fungal infections play a crucial role in supporting market growth. The integration of molecular diagnostics and the advent of new biomarkers are anticipated to revolutionize the diagnostics landscape, leading to enhanced patient care and management.

Growth Factor of the Market

The Invasive Fungal Disease Infection Diagnostic Reagent Market is experiencing substantial growth due to several interrelated factors. Firstly, the rise in the prevalence of chronic diseases such as diabetes and cancer, which compromise the immune system and increase susceptibility to fungal infections, is a major driver. Secondly, the expansion of the geriatric population, who are more vulnerable to infections due to age-related immune decline, further fuels market demand. Advances in technology, particularly in molecular diagnostics, facilitate rapid and precise detection, which is essential for effective treatment outcomes. Additionally, growing awareness about fungal diseases among healthcare professionals and the public is contributing to increased testing rates. Furthermore, supportive government policies and funding to promote research and develop innovative diagnostic solutions are creating a conducive environment for market growth.

Key Highlights of the Market

• The global IFD diagnostic reagent market is projected to reach USD 1.2 billion by 2035.
• Expected CAGR of 8.5% from 2025 to 2035.
• Significant rise in chronic diseases driving market demand.
• Technological advancements in molecular diagnostics enhance detection capabilities.
• Growing awareness and government initiatives to promote research in fungal infections.

By Product Type

PCR Kits:

PCR (Polymerase Chain Reaction) kits are essential tools in the diagnostics of Invasive Fungal Diseases, enabling the detection of fungal DNA with high sensitivity and specificity. These kits have become increasingly popular due to their rapid turnaround time and the ability to detect multiple pathogens simultaneously. The growing adoption of these kits in clinical laboratories is driven by their efficacy in diagnosing difficult-to-detect fungal infections, particularly in immunocompromised patients. Moreover, as the prevalence of such diseases rises, the demand for PCR kits is expected to witness a corresponding increase. Regulatory approvals and advancements in the technology used in these kits will further bolster their market presence, making them a key segment within the IFD diagnostic reagents market.

Immunoassays:

Immunoassays are widely utilized in the diagnosis of invasive fungal infections due to their ability to identify specific antigens or antibodies related to fungal pathogens. This method is particularly beneficial in detecting infections in patients with underlying health conditions, as it provides timely results that can guide treatment decisions. The increasing focus on early diagnosis to improve patient outcomes is contributing to the growth of the immunoassays segment. Additionally, the development of novel immunoassay platforms that enhance sensitivity and reduce the time required for tests is anticipated to further drive the adoption of these diagnostic tools in clinical settings. The versatility and reliability of immunoassays continue to position them as a critical component in the diagnostic arsenal against invasive fungal diseases.

Microscopy Instruments:

Microscopy instruments, including fluorescence and light microscopes, are vital for the visualization and identification of fungal structures in clinical samples. These tools are essential for confirming a diagnosis, particularly in cases where culture and molecular techniques may not provide immediate results. The growing number of clinical laboratories equipped with advanced microscopy techniques is expected to promote the demand for these instruments. Their effectiveness in providing rapid feedback in critical patient cases enhances their value in diagnostic workflows. Moreover, ongoing innovations in microscopy technology, such as digital imaging and automation, are likely to increase their application in diagnosing invasive fungal diseases, solidifying their role in the overall market.

Biomarker Assays:

Biomarker assays play a significant role in the early diagnosis and monitoring of invasive fungal infections, focusing on specific biological markers released in response to fungal pathogens. These assays offer the advantage of high specificity, which is crucial in differentiating between fungal and non-fungal infections. As research progresses in identifying new biomarkers associated with various fungal species, the market for these assays is expected to expand. Moreover, the integration of biomarker assays into routine diagnostic practices can facilitate more personalized treatment approaches, enhancing patient management. The potential for innovation in biomarker discovery will further enhance the growth prospects of this segment within the IFD diagnostic reagent market.

Culture Media:

Culture media are indispensable for the isolation and identification of fungal pathogens from clinical specimens. The demand for various types of culture media continues to grow, driven by the necessity of accurately diagnosing invasive fungal infections in clinical microbiology laboratories. This segment has seen advancements through the development of selective culture media that enhance the growth of specific fungi while inhibiting others. Moreover, the increasing emphasis on laboratory automation and standardization is likely to bolster the use of culture media in diagnostic settings. As the global burden of fungal infections rises, the culture media segment will remain a cornerstone in the diagnostic process, ensuring timely and accurate identification of the pathogens responsible for invasive fungal diseases.

By Application

Hospitals:

The hospital sector is a primary application area for invasive fungal disease diagnostics, as hospitals encounter many patients at risk of fungal infections due to various underlying health complications. Hospitals are increasingly investing in advanced diagnostic technologies to ensure rapid and accurate identification of fungal pathogens, which is critical in preventing severe complications and improving patient outcomes. The implementation of robust laboratory services within hospitals allows for immediate testing and timely treatment initiation, thus significantly reducing morbidity and mortality associated with these infections. The growing number of hospital admissions due to chronic diseases and the rise of immunocompromised patients directly contribute to the expanding demand for diagnostic reagents in this sector.

Diagnostic Centers:

Diagnostic centers play a crucial role in the early detection and management of invasive fungal diseases, providing specialized testing services that complement hospital laboratories. These centers often have the capability to perform a wide range of diagnostic tests, including serological and molecular assays. The increasing prevalence of fungal infections and the subsequent rise in demand for accurate diagnostic services have led to the establishment of more diagnostic centers globally. These centers often utilize advanced technologies, enabling them to deliver results quickly and efficiently, thereby enhancing patient care. Furthermore, partnerships between hospitals and diagnostic centers are becoming more common to facilitate better patient outcomes through coordinated testing approaches, further driving this application's growth.

Research Institutes:

Research institutes are vital for advancing the understanding of invasive fungal diseases, focusing on the development of novel diagnostic tools and therapies. These institutions conduct extensive studies that contribute to the identification of new fungal biomarkers and the evaluation of diagnostic methods. The increasing investment in fungal research, driven by the growing recognition of the public health challenge posed by these infections, supports the continuous demand for diagnostic reagents within these settings. Collaborations between research institutes and diagnostic companies often lead to the innovation of new products and solutions that enhance diagnostic capabilities and ultimately improve patient management. The output of research initiatives significantly influences the market dynamics of invasive fungal disease diagnostic reagents.

Other:

This category encompasses a range of applications for invasive fungal disease diagnostics, including veterinary diagnostics, blood banks, and specialized laboratories. The need for effective diagnostic tools in these areas is driven by the rising awareness of the impact of fungal infections beyond human health, particularly in animal health and safety. Additionally, blood banks require accurate testing to ensure the safety of transfusion procedures, highlighting the importance of diagnostic reagents in preventing fungal contamination. The growth of this segment is anticipated to be fueled by the expansion of diagnostic capabilities across different sectors, reflecting a broader recognition of the need for comprehensive fungal infection management strategies.

By Distribution Channel

Hospitals Pharmacies:

Hospital pharmacies are critical distribution channels for invasive fungal disease diagnostic reagents, as they serve as the primary suppliers of diagnostic products within the healthcare system. These pharmacies are well-positioned to provide hospital laboratories with the necessary reagents and equipment required for accurate and timely fungal diagnostics. The integration of diagnostic reagents into hospital pharmacy operations facilitates streamlined access for healthcare professionals, ensuring that testing can be conducted rapidly. As hospitals increasingly recognize the importance of early diagnosis in improving patient outcomes, the demand for diagnostic reagents through hospital pharmacies is expected to expand, supported by strategic partnerships with manufacturers.

Retail Pharmacies:

Retail pharmacies are emerging as significant distribution channels for invasive fungal disease diagnostic reagents, particularly in providing over-the-counter testing kits for consumers. The growing prevalence of fungal infections and the heightened awareness of self-diagnosis have led to an increase in demand for accessible testing solutions available at retail locations. Retail pharmacies are increasingly partnering with diagnostic companies to offer a range of products, including kits that enable patients to conduct preliminary tests at home. This trend reflects a broader shift toward consumer empowerment in health management and is expected to drive growth in this distribution channel, enhancing the overall accessibility of diagnostic reagents.

Online Sales:

The online sales channel for invasive fungal disease diagnostic reagents is witnessing rapid growth, driven by the increasing comfort and preference for online shopping among consumers and healthcare professionals. E-commerce platforms provide a convenient avenue for purchasing diagnostic products, often at competitive prices. The COVID-19 pandemic has accelerated the adoption of online sales channels, as healthcare providers and laboratories seek to minimize in-person interactions while ensuring access to essential diagnostic reagents. Additionally, many diagnostic companies are investing in their online presence to facilitate direct sales and streamline distribution processes. As online shopping becomes increasingly ingrained in purchasing habits, this distribution channel is likely to play a critical role in shaping the market landscape.

By Testing Type

Serological Tests:

Serological tests are widely used for the diagnosis of invasive fungal diseases by detecting specific antibodies or antigens in a patient's serum. These tests are instrumental in evaluating the immune response to fungal infections, providing valuable information that can aid in diagnosis and treatment decisions. The growing trend towards implementing serological testing in clinical practice stems from its ability to provide rapid results, which is crucial in managing acute infections. As healthcare professionals increasingly recognize the importance of timely diagnosis, the demand for serological tests is expected to increase. Furthermore, advancements in serological testing technologies, such as enhanced sensitivity and specificity, will likely contribute to the growth of this segment in the overall market.

Molecular Diagnostic Tests:

Molecular diagnostic tests have transformed the landscape of invasive fungal disease diagnostics by enabling the rapid and accurate identification of fungal DNA and RNA. These tests are particularly beneficial in cases where traditional culture methods may take longer or yield inconclusive results. The increasing adoption of molecular diagnostic techniques in clinical laboratories is driven by their ability to deliver faster results and improve diagnostic accuracy. Additionally, the evolution of multiplex testing platforms allows for the simultaneous detection of multiple fungal pathogens, further enhancing the utility of molecular diagnostics in patient management. As the focus on precision medicine continues to grow, this segment is expected to witness significant advancements and increased market demand.

Biopsy:

Biopsy testing is a critical method for diagnosing invasive fungal diseases, particularly in cases where there is a need for direct visualization of fungal elements within tissue samples. This invasive procedure allows for definitive diagnosis and is often utilized when non-invasive tests are inconclusive. The demand for biopsy testing is driven by the necessity of accurate fungal identification, especially in severe cases where rapid intervention is essential. As advancements in biopsy techniques and technologies continue to evolve, including minimally invasive approaches, the acceptance and application of biopsy testing in clinical practice are expected to increase. This segment remains vital for providing conclusive evidence of fungal infections, reinforcing its significance in the diagnostic reagent market.

By Region

North America holds a substantial share of the Invasive Fungal Disease Infection Diagnostic Reagent Market, driven by a robust healthcare infrastructure and a high prevalence of fungal infections among immunocompromised patients. The increasing incidence of conditions such as diabetes, cancer, and HIV/AIDS contributes to the rising demand for effective diagnostic reagents in this region. Furthermore, the presence of leading diagnostic companies and ongoing research initiatives focused on improving fungal diagnostics are expected to propel market growth in North America. The region exhibits a projected CAGR of 8.0% from 2025 to 2035, reflecting the commitment to enhancing diagnostic capabilities and patient care.

In Europe, the growth of the Invasive Fungal Disease Infection Diagnostic Reagent Market is supported by the increasing awareness of fungal infections and the implementation of strict regulations to ensure quality testing. The presence of advanced healthcare systems and a growing focus on infectious disease management further drives market demand. Countries such as Germany, France, and the UK are leading the market due to their established healthcare infrastructure and investments in research. The European market is expected to experience steady growth, with a CAGR of approximately 7.5% over the forecast period, as healthcare authorities prioritize the development and adoption of innovative diagnostic solutions.

Opportunities

The Invasive Fungal Disease Infection Diagnostic Reagent Market presents numerous opportunities driven by technological advancements and an increasing focus on precision medicine. The rapid evolution of molecular diagnostic techniques is a prime opportunity, as these methods offer enhanced sensitivity and specificity in detecting fungal pathogens. With the development of multiplex assays that can identify multiple fungi simultaneously, diagnostic laboratories are expected to adopt these technologies at an accelerating pace. Furthermore, collaborations between diagnostic companies and healthcare providers can pave the way for innovative solutions that cater to unmet needs in fungus diagnostics, particularly in remote and underserved areas. The growth of telemedicine and home-testing solutions also opens avenues for broader access to diagnostic tests, enabling more individuals to seek timely care.

Another significant opportunity in the market is the increasing global investment in research and development aimed at improving fungal diagnostics. As the awareness of the burden posed by invasive fungal diseases grows, more funding is directed towards developing new diagnostic tools and expanding existing testing capabilities. The integration of artificial intelligence and machine learning in diagnostics can further enhance the accuracy and speed of test results. Furthermore, as global health organizations emphasize the importance of diagnosing and managing fungal infections, there is an opportunity for diagnostic companies to align their innovations with public health initiatives. This alignment can lead to increased market penetration and ultimately improve patient outcomes on a global scale.

Threats

Despite the positive outlook for the Invasive Fungal Disease Infection Diagnostic Reagent Market, several threats could impede its growth. One significant threat is the presence of stringent regulatory frameworks governing the approval and use of diagnostic reagents, which can delay the introduction of innovative products into the market. Companies must navigate complex approval processes in different regions, which can be time-consuming and costly. Additionally, the rapid pace of technological advancements means that diagnostic firms must continuously invest in research and development to remain competitive. Failure to keep up with innovations can result in obsolescence, particularly for companies that rely on traditional diagnostic methods. The emergence of new pathogens and the evolving nature of fungal infections also present challenges, as diagnostic solutions must adapt to identify these evolving threats effectively.

Another significant threat to the market is the potential for market saturation, particularly in regions with established diagnostic capabilities. As more companies enter the market, competition can lead to price wars that pressure profitability. This situation is further exacerbated by the presence of alternative diagnostic solutions that may offer similar or enhanced capabilities. Companies must therefore focus on differentiating their products and demonstrating superior clinical value to maintain market share. Additionally, the economic climate and shifts in healthcare funding could impact the availability of resources for diagnostics, potentially reducing investment in innovative solutions and limiting overall market growth.

Competitor Outlook

• Thermo Fisher Scientific
• Roche Diagnostics
• Abbott Laboratories
• Bio-Rad Laboratories
• BD (Becton, Dickinson and Company)
• Qiagen
• Hologic, Inc.
• Merck KGaA
• GenMark Diagnostics
• Biomerieux
• F. Hoffmann-La Roche AG
• Ortho Clinical Diagnostics
• Cepheid (Danaher Corporation)
• Agilent Technologies
• DiaSorin S.p.A.

The competitive landscape of the Invasive Fungal Disease Infection Diagnostic Reagent Market is characterized by a diverse array of players, ranging from established multinational corporations to specialized companies focused exclusively on diagnostics. Leading companies such as Thermo Fisher Scientific and Roche Diagnostics dominate the market due to their extensive product portfolios and significant investments in research and development. These companies leverage their technological capabilities to introduce innovative diagnostic reagents that meet the evolving needs of healthcare providers and patients. Additionally, collaborations and partnerships between firms are common in this landscape, enabling companies to enhance their product offerings and penetrate new markets effectively.

Another key aspect of the competitive landscape is the emergence of niche players that focus on specific segments of the market, such as molecular diagnostics or serological tests. These specialized companies often capitalize on innovative technologies and agile business models to differentiate themselves from larger competitors. For instance, firms like GenMark Diagnostics and Hologic, Inc. have gained recognition for their rapid diagnostic solutions, catering to the growing demand for timely testing. The ability to respond swiftly to market trends and advancements in technology positions these companies favorably in an increasingly competitive environment. Furthermore, the ongoing emphasis on research and development by these emerging players fosters a culture of innovation, driving the overall market forward.

As the market continues to evolve, major companies are also focusing on strategic mergers and acquisitions to strengthen their positions and expand their market reach. These activities enable companies to integrate new technologies and capabilities, enhancing their competitive edge. Moreover, companies are increasingly investing in digital health solutions, recognizing the growing importance of telemedicine and remote patient monitoring. This shift not only helps in expanding their product offerings but also aligns with evolving consumer preferences for accessible and convenient healthcare solutions. Overall, the competitive landscape of the Invasive Fungal Disease Infection Diagnostic Reagent Market is dynamic and characterized by continuous innovation, strategic collaborations, and an unwavering commitment to improving diagnostic capabilities.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Qiagen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Biomerieux
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Merck KGaA
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Hologic, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 DiaSorin S.p.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 GenMark Diagnostics
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Agilent Technologies
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Bio-Rad Laboratories
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 F. Hoffmann-La Roche AG
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Ortho Clinical Diagnostics
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Cepheid (Danaher Corporation)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 BD (Becton, Dickinson and Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Invasive Fungal Disease IFD Infection Diagnostic Reagent Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Centers
    • 6.1.3 Research Institutes
    • 6.1.4 Other
  • 6.2 Invasive Fungal Disease IFD Infection Diagnostic Reagent Market, By Testing Type
    • 6.2.1 Serological Tests
    • 6.2.2 Molecular Diagnostic Tests
    • 6.2.3 Biopsy
  • 6.3 Invasive Fungal Disease IFD Infection Diagnostic Reagent Market, By Distribution Channel
    • 6.3.1 Hospitals Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Invasive Fungal Disease IFD Infection Diagnostic Reagent Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Invasive Fungal Disease IFD Infection Diagnostic Reagent market is categorized based on

By Application

• Hospitals
• Diagnostic Centers
• Research Institutes
• Other

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Sales

By Testing Type

• Serological Tests
• Molecular Diagnostic Tests
• Biopsy

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific
• Roche Diagnostics
• Abbott Laboratories
• Bio-Rad Laboratories
• BD (Becton, Dickinson and Company)
• Qiagen
• Hologic, Inc.
• Merck KGaA
• GenMark Diagnostics
• Biomerieux
• F. Hoffmann-La Roche AG
• Ortho Clinical Diagnostics
• Cepheid (Danaher Corporation)
• Agilent Technologies
• DiaSorin S.p.A.